Search PubMed⌕ Search

Biomedical subjects

G Schellong

Publications and source records attributed to G Schellong.

At least 73 records · Page 4Linked to original sources
PubMed1985

Treatment of acute myelogenous leukemia in children.

Progress in the treatment of childhood AML has not equalled the advances obtained in the management of ALL. Two recent chemotherapy studies (i.e. VAPA and BFM 78), however, reported marked increase in the proportion of long-term remissions. The initial therapy of the cooperative study BFM 78 consisted of two 4-week phases of intensive induction/consolidation with 7 different drugs and cranial irradiation followed by maintenance with thioguanine and cytosine arabinoside for 2 years and additional adriamycin during the first year. A total of 151 children with AML were enrolled in the study from 30 centers. Of these 119 (79%) patients achieved complete remission. After a median observation time of 34 (14-57) months, there have been 46 relapses. CNS was involved in 6 of these relapses. Life table analyses revealed the following probabilities after 4 1/2 years: survival: 46%; disease-free survival: 41% (total group), 52% (remission group); disease-free interval 56% (remission group). The risk of relapse appears to decrease considerably after 2 1/2 years. No risk factors for the occurrence of relapse have been identified.

Adolescent↗
PubMed1985

What's new in pediatric oncology? Epidemiology, treatment principles and prognosis in childhood malignancies.

The proportion of malignancies in children differs from that in adults: Leukemias and malignant lymphomas predominate with a total of 50%, followed by tumors of the nervous system, of the kidneys, and of connective and supportive tissue. Most of these diseases respond well to cytostatic therapy. Therefore chemotherapy occupies a major role in the curative concepts for nearly all childhood malignancies. Its objective is the destruction of micrometastases as well as the reduction of primary tumor mass in inoperable cases, and it often helps to limit the extent of radical surgery. Radiotherapy, too, can be reduced under the influence of cytostatic therapy. In nearly all childhood cancers, prognosis has improved substantially over the past 10 to 15 years. Today, our aim is not the mere limited survival, but a definitive cure. Modern strategies have raised the cure rates of Hodgkin's disease to 90%, of Wilms' tumor, acute lymphoblastic leukemia and non- Hodgkin lymphomas to 70-75%, of soft tissue sarcomas and osteosarcomas to about 50%, and of acute myelogenous leukemia, neuroblastoma and medulloblastoma to 30-35%. Centralized management of childhood cancers in specially staffed hospitals is mandatory on account of their relative low frequency, the risks of chemotherapy, and the high staff workload.

Adolescent↗
PubMed1984

[Graded chemotherapy and reduced radiotherapy in Hodgkin's disease in childhood. Intermediate report on the cooperative HD 82 therapy study].

The results of 111 children with Hodgkin's disease, who were treated with chemotherapy of different intensity and reduced radiotherapy (Cooperative Therapy Study HD 82, 12/81 - 9/83) are presented. There is no evidence that reduction of radiotherapy and selective splenectomy (splenectomy only in case of high probability of splenic involvement) induce a higher rate of relapses. All 87 patients with pathological stage I, II and IIIA are in first remission. 2 of 24 patients with stage IIIB/IV died of sepsis, 1 of those 24 patients relapsed. Splenectomy could be omitted in 2/3 of patients, in 75% of splenectomy splenic involvement was proved. 7% of all children get splenic irradiation.

Adolescent↗
PubMed1984

Pituitary-gonadal function in boys after high dose testosterone treatment for excessively tall stature.

One hundred excessively tall boys with a height prediction of 205.32 +/- 5.28 cm (mean +/- SD) were treated with 500 mg testosterone oenanthate (TE) every 14 days for a period of 14.96 +/- 5.29 months. Following therapy, the hypothalamo-pituitary-gonadal axis was evaluated, using a standardized GnRH-test at median time intervals of 14 days, 6 weeks, 13 weeks, 6 months and 16 months. Basal and stimulated LH- and FSH-values were not measurable or severely suppressed in all boys 14 days after termination of therapy. Starting at 6 weeks, normalization of pituitary-gonadal function was demonstrated in 93 boys (group 1) with follow-up periods of up to 48 months. Six boys (group 2) developed transitory hypergonadotrophic LH- and FSH-secretory patterns for up to 11 months after the last TE-injection. Testosterone and gonadotrophins were within the normal range in all 6 boys, when prospectively re-evaluated at 12 to 27 months after termination of therapy. During TE-administration, testicular volume was reduced in some, and in most boys did not show the normal enlargement occurring during puberty. However, return to normal testicular size was seen several months after treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗
PubMed1983

[Familial hypogonadism with anosmia: Kallmann Syndrome].

The familial occurrence of hypogonadism and anosmia (Kallmann-Syndrome) is reported in a 15 5/12 year old boy and his 20 7/12 year old sister, who in addition has a ventricular septal defect. To establish the diagnosis it is important to examine the patient with hypogonadism for anosmia since voluntary information is rarely obtained. Quite often there are additional, associated anomalies which have to be searched for carefully.

Adolescent↗
PubMed1981

[Testosteron treatment of excessively tall boys (author's transl)].

Twenty-five boys aged 11.7-16.8 years with constitutionally tall stature were treated with 500 mg testosteron oenanthate two-weekly over a period of 15.6 months on average. Prediction of height was done according to Bayley-Pinneau (BP) and Tanner et al. with a mean parent height of 168 cm (T168) and 172 cm (T172). It was on average at 202.73 cm (BP) and 203.26 cm (T168) or 201.97 (T172). The achieved height reduction was 7.2 cm (BP), 7.73 cm (T168) and 6.44 cm (T172), corresponding to a reduction of 45.6% (BP), 47.3% (T168) and 41% (T172) of the future growth. Whereas the major reductions were obtained in the youngest patients, success of treatment in patients with a skeletal age of 15 and more years was not demonstrable with certainty. Predominant side effects were weight gain within the first 6 months, acne and transient reduction of testicular volume.

Acne Vulgaris↗
PubMed1981

[Acute leukemia in a 13-year old boy with a synchronous occurrence of lympho- and monoblasts (author's transl)].

The synchronous occurrence of blasts of the lymphatic and myelogenous lineage in acute leukemia has been rarely observed. Reviewing individual case reports it is suggested that malignant transformation already starts at the level of the stem cell. We are reporting a case of a 13-year old boy who initially showed morphological features of acute lymphatic leukemia. Following 14 days of therapy the assumption of a pure lymphatic lineage has to be changed in favour for monoblasts which are now occurring.

Acute Disease↗
PubMed1981

Thymic involvement and initial white blood count in childhood acute lymphoblastic leukemia.

From 1970 to 1977, two nonrandomized groups of children with acute lymphoblastic leukemia (ALL) were treated with two different induction regimens. A total of 168 patients (group DAL) received induction therapy closely adapted to St. Jude protocol VII. A total of 119 patients (group BFM) were treated with the West Berlin induction protocol. Evaluable for analysis were 138 patients of group DAL and 113 patients of group BFM. Thirty children had thymic involvement (Thy+), 15 in each group. In children without thymic involvement (Thy+), the median initial white blood count (WBC) was 8400/mm3 in group DAL and 8000/mm3 in group BFM. In contrast, the initial WBC was 42,000/mm3 and 79,200/mm3 in the corresponding group with thymic involvement (Thy+). The probability of continuous complete remission (CCR) at 9 years is 0.41 +/- 0.05 for patients without thymic involvement and 0.09 +/- 0.09 for patients with thymic involvement in group DAL, and 0.65 +/- 0.05 for those without thymic involvement and 0.52 +/- 0.13 for those who had thymic involvement in group BFM. After adjustment for initial WBC (regression analysis) the presence of thymic involvement was still a predictor of poor outcome in group DAL (p less than 0.001), whereas it was not a predictor of poor response in group BFM. In view of comparable patient composition in both treatment groups, the favorable prognosis in BFM patients has to be related to the mode of induction therapy.

Adolescent↗